18201-61-1

Basic information

• Product Name: 2-(2,6-DIMETHYL-PHENYLAMINO)-BENZOIC ACID
• Synonyms: 2-(2,6-DIMETHYL-PHENYLAMINO)-BENZOIC ACID;AKOS 93764;N-(2,6-DIMETHYLPHENYL)ANTHRANILIC ACID
• CAS NO: 18201-61-1
• Molecular Formula: C₁₅H₁₅NO₂
• Molecular Weight: 241.2851
• Product Categories: pharmacetical
• Mol File: 18201-61-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 389.9°Cat760mmHg
• Flash Point: 189.6°C
• Appearance: /
• Density: 1.203g/cm³
• Vapor Pressure: 8.88E-07mmHg at 25°C
• Refractive Index: 1.639
• CAS DataBase Reference: 2-(2,6-DIMETHYL-PHENYLAMINO)-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,6-DIMETHYL-PHENYLAMINO)-BENZOIC ACID(18201-61-1)
• EPA Substance Registry System: 2-(2,6-DIMETHYL-PHENYLAMINO)-BENZOIC ACID(18201-61-1)

Safety Data

• Hazardous Substances Data: 18201-61-1(Hazardous Substances Data)

Usage

Soluble in organic solvents

ethanol, acetone, and ethyl acetate This indicates that the compound can dissolve in certain organic solvents, specifically ethanol, acetone, and ethyl acetate, which is a common property of many organic compounds.
Used in the pharmaceutical industry as a building block in the synthesis of various drugs and active pharmaceutical ingredients This describes one of the main uses of the compound, which is as a starting material or intermediate in the production of various drugs and active pharmaceutical ingredients.
Can also be used as a dye intermediate and in the production of pigments and other organic compounds This indicates that the compound has other uses beyond the pharmaceutical industry, such as in the production of dyes and pigments.
Shown potential anti-inflammatory and analgesic effects in preliminary studies This suggests that the compound has potential therapeutic effects, specifically in reducing inflammation and pain, which makes it a promising candidate for further research and development in the field of medicinal chemistry.

InChI:InChI=1/C15H15NO2/c1-10-6-5-7-11(2)14(10)16-13-9-4-3-8-12(13)15(17)18/h3-9,16H,1-2H3,(H,17,18)

Upstream product

• 16463-38-0 potassium 2-chlorobenzoate 
• 87-62-7 2,6-dimethylaniline 
• 1488-42-2 Diphenyliodonium-2-carboxylate 
• 16497-87-3 potassium o-bromobenzoate 
• 17264-73-2 sodium o-bromobenzoate 
• 118-91-2 ortho-chlorobenzoic acid 
• 88-65-3 2-bromobenzoic-acid 

Downstream Products

• 4058-04-2 N-phenyl-2,6-dimethylaniline 
• 65-85-0 benzoic acid 
• 87-62-7 2,6-dimethylaniline 
• 13625-38-2 2-((2,6-dimethylphenyl)amino)benzamide 
• 86365-67-5 1-(2,6-dimethylphenyl)-3-<(2,6-dimethylphenyl)amino>-2-phenylindole 
• 86365-68-6 N'-benzoyl-N,N'-bis(2,6-dimethylphenyl)anthranilamide 
• 13850-62-9 2-((2,6-dimethylphenyl)amino)benzonitrile 
• 677004-90-9 bis-2-[(2,6-dimethylphenyl)amino]benzoato-di-n-butyltin(IV) 
• 677004-89-6 1,2:3,4-diμ2-[(2,6-dimethylphenyl)amino]benzoato-O,O-1,3-bis-2-[(2,6-dimethylphenyl)amino]benzoato-O-1,2,4:2,3,4-di-μ3-oxo-tetrakis[di-butyltin(IV)] 

Relevant articles and documents

Solution growth and thermal treatment of crystals lead to two new forms of 2-((2,6-dimethylphenyl)amino)benzoic acid

We report the discovery of two new forms (II and III) of a potential non-steroidal anti-inflammatory and thyroid drug, 2-((2,6-dimethylphenyl)amino)benzoic acid (HDMPA) through solution growth and thermal treatment of crystals. Form II has been discovered

The triphenyltin(VI) complexes of NSAIDs and derivatives. Synthesis, crystal structure and antiproliferative activity. Potent anticancer agents

The novel triphenyltin(IV) esters of flufenamic acid (1), Hflu, [Ph 3Sn(flu)] (2), and of [2-(2,3-dichlorophenylamino)benzoic acid] (3), Hdcpa, [Ph3Sn(dcpa)] (4) have been structurally characterized by means of vibrational and 1H, 13C NMR spectroscopic studies. The crystal and molecular structures of [SnPh3(dcpa)(DMSO)] 4a are described. The molecular structure of 4a reveals that the Sn atom has a distorted trigonal bipyramidal coordination geometry with equatorial phenyl groups and the carboxylate and dimethylsulfoxide oxygen atoms occupying axial positions. The crystal structure of 4a is self-assembled by C-H - -π and π-π stacking interactions. The in vitro cytotoxic activity of 1-4 and of the related non-steroidal anti-inflammatory drugs, NSAIDs, [2-(2,6- dimethylphenylamino)benzoic acid], Hdmpa (5), [Ph3Sn(dmpa)] (6), [2-(2,3-dimethylphenylamino)benzoic acid], mefenamic acid, Hmef (7) and [Ph 3Sn(mef)] (8) has been evaluated against the cancer cell lines MCF-7, T-24, A-549 and L-929. The ligands exhibited very poor cytotoxic activity against the four cancer cell lines. Complex 6 exhibits the highest activity and selectivity against A-549 and MCF-7 cancer cell lines and complex 8 the highest activity and selectivity against T-24 cancer cell line. The cytotoxic results indicate that coupling of Hdmpa and Hmef with R3Sn(IV) metal center results in complexes with important biological properties and remarkable cytotoxic activity, since they display IC50 values in a μΜ range better to that of the antitumor drug cis-platin. Complexes 6 and 8 are considered as excellent antitumor compounds and the results of this study represent the discovery of triphenyltin(IV)esters as a potential novel class of anticancer agents.

Regioselective copper-catalyzed amination of bromobenzoic acids using aliphatic and aromatic amines

A chemo- and regioselective copper-catalyzed cross-coupling procedure for amination of 2-bromobenzoic acids is described. The method eliminates the need for acid protection and produces N-aryl and N-alkyl anthranilic acid derivatives in up to 99% yield. N-(1-Pyrene)anthranilic acid has been employed in metal ion-selective fluorosensing. Titration experiments showed that this pyrene-derived amino acid forms an equimolar complex with Hg(II) in water resulting in selective fluorescence quenching even in the presence of other metal ions such as Zn(II) and Cd(II).